David Amsellem
Stock Analyst at Piper Sandler
(4.86)
# 360
Out of 4,630 analysts
921
Total ratings
61.9%
Success rate
15.7%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Reiterated: Hold | $21 → $20 | $20.78 | -3.75% | 41 | Aug 7, 2026 | |
| COLL Collegium Pharmaceutical | Reiterated: Hold | $44 → $43 | $29.47 | +45.91% | 46 | Aug 7, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $73 → $75 | $46.14 | +62.55% | 6 | Aug 7, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterated: Hold | $8 | $7.93 | +0.88% | 14 | Aug 7, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $65 | $49.17 | +32.19% | 42 | Aug 6, 2026 | |
| AMGN Amgen | Reiterated: Buy | $427 | $410.95 | +3.91% | 50 | Aug 5, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $301 → $310 | $256.56 | +20.83% | 68 | Aug 4, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $207 → $210 | $163.41 | +28.51% | 43 | Jul 31, 2026 | |
| CORT Corcept Therapeutics | Reiterated: Buy | $88 → $165 | $110.77 | +48.96% | 33 | Jul 30, 2026 | |
| BIIB Biogen | Rated: Buy | $225 | $207.94 | +8.20% | 31 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $75 | $64.72 | +15.88% | 18 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $42 → $44 | $35.36 | +24.43% | 70 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $298 | $246.04 | +21.12% | 25 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 | $47.64 | +38.54% | 70 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $18.14 | -6.28% | 42 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $258 | $212.74 | +21.27% | 26 | Jul 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | $12 | $16.43 | -26.96% | 24 | Jun 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $59 | $38.82 | +51.98% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $11.58 | +55.51% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $3.94 | +103.05% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $5 → $14 | $13.60 | +2.94% | 18 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $94 → $111 | $78.25 | +41.85% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $38.41 | +19.76% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $28.36 | +69.25% | 3 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $9 | $9.60 | n/a | 19 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $25.02 | n/a | 39 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $4.20 | $8.70 | n/a | 64 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $18 | $4.32 | n/a | 9 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $12 | $1.87 | n/a | 12 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $26 → $17 | $0.0509 | n/a | 29 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2 | $0.008 | n/a | 7 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $3 | $41.43 | n/a | 5 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $6 → $175 | $0.000001 | n/a | 7 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $26.76 | n/a | 1 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $1.43 | n/a | 10 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.0002 | n/a | 1 | Nov 11, 2013 |
Amphastar Pharmaceuticals
Aug 7, 2026
Reiterated: Hold
Price Target: $21 → $20
Current: $20.78
Upside: -3.75%
Collegium Pharmaceutical
Aug 7, 2026
Reiterated: Hold
Price Target: $44 → $43
Current: $29.47
Upside: +45.91%
Definium Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $73 → $75
Current: $46.14
Upside: +62.55%
Xeris Biopharma Holdings
Aug 7, 2026
Reiterated: Hold
Price Target: $8
Current: $7.93
Upside: +0.88%
Alkermes
Aug 6, 2026
Reiterated: Buy
Price Target: $65
Current: $49.17
Upside: +32.19%
Amgen
Aug 5, 2026
Reiterated: Buy
Price Target: $427
Current: $410.95
Upside: +3.91%
Jazz Pharmaceuticals
Aug 4, 2026
Reiterated: Buy
Price Target: $301 → $310
Current: $256.56
Upside: +20.83%
Neurocrine Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: $207 → $210
Current: $163.41
Upside: +28.51%
Corcept Therapeutics
Jul 30, 2026
Reiterated: Buy
Price Target: $88 → $165
Current: $110.77
Upside: +48.96%
Biogen
Jul 28, 2026
Rated: Buy
Price Target: $225
Current: $207.94
Upside: +8.20%
Jul 28, 2026
Rated: Buy
Price Target: $75
Current: $64.72
Upside: +15.88%
Jul 28, 2026
Rated: Buy
Price Target: $42 → $44
Current: $35.36
Upside: +24.43%
Jul 28, 2026
Rated: Buy
Price Target: $298
Current: $246.04
Upside: +21.12%
Jul 27, 2026
Reiterated: Buy
Price Target: $66
Current: $47.64
Upside: +38.54%
Jul 20, 2026
Reiterated: Buy
Price Target: $17
Current: $18.14
Upside: -6.28%
Jul 14, 2026
Reiterated: Buy
Price Target: $258
Current: $212.74
Upside: +21.27%
Jun 4, 2026
Maintained: Hold
Price Target: $12
Current: $16.43
Upside: -26.96%
May 22, 2026
Reiterated: Buy
Price Target: $54 → $59
Current: $38.82
Upside: +51.98%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $11.58
Upside: +55.51%
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $3.94
Upside: +103.05%
Apr 28, 2026
Upgraded: Hold
Price Target: $5 → $14
Current: $13.60
Upside: +2.94%
Apr 23, 2026
Maintained: Buy
Price Target: $94 → $111
Current: $78.25
Upside: +41.85%
Apr 22, 2026
Reiterated: Buy
Price Target: $48 → $46
Current: $38.41
Upside: +19.76%
Apr 20, 2026
Reiterated: Buy
Price Target: $48
Current: $28.36
Upside: +69.25%
Mar 21, 2025
Downgraded: Hold
Price Target: $15 → $9
Current: $9.60
Upside: n/a
Nov 7, 2024
Reiterated: Hold
Price Target: $11 → $12
Current: $25.02
Upside: n/a
Oct 31, 2024
Reiterated: Sell
Price Target: $4.20
Current: $8.70
Upside: n/a
May 22, 2024
Reiterated: Buy
Price Target: $21 → $18
Current: $4.32
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $1 → $12
Current: $1.87
Upside: n/a
Aug 9, 2023
Downgraded: Sell
Price Target: $26 → $17
Current: $0.0509
Upside: n/a
May 25, 2022
Maintained: Buy
Price Target: $2
Current: $0.008
Upside: n/a
Nov 10, 2021
Reiterated: Buy
Price Target: $20 → $3
Current: $41.43
Upside: n/a
May 6, 2021
Maintained: Buy
Price Target: $6 → $175
Current: $0.000001
Upside: n/a
Jan 23, 2019
Upgraded: Hold
Price Target: n/a
Current: $26.76
Upside: n/a
Oct 12, 2017
Reiterated: Hold
Price Target: $3 → $2
Current: $1.43
Upside: n/a
Nov 11, 2013
Initiated Coverage: Buy
Price Target: $6
Current: $0.0002
Upside: n/a